Aspira Women`s Health Inc Stock Price, News & Analysis

Aspira Women’s Health Inc. (AWH) appointed Minh Merchant as General Counsel and Corporate Secretary, effective January 4, 2022. With extensive experience in healthcare law, Merchant's previous roles include General Counsel at Genome Medical and Associate General Counsel at Myriad Genetics. CEO Valerie Palmieri expressed confidence in Merchant's ability to contribute strategically to the company, known for its innovative women's health solutions. Aspira focuses on improving gynecologic health outcomes, particularly in ovarian cancer risk assessment, and aims to enhance access to specialty tests through its new technology transfer platform.

Aspira Women’s Health Inc. (AWH) reported a strong third quarter with a 34% revenue increase to $1.67 million and a 19% rise in OVA1 test volume to 4,281 units. The company successfully completed Phase 1 of its collaboration with Harvard Dana Farber Cancer Institute. Their OVA1 test now covers over 194 million lives, marking an 8% increase. Despite these gains, expenses surged, with R&D costs up by 155% and marketing expenses up 136%. The company ended the quarter with $44.9 million in cash but reported a cash usage increase to $7.9 million.

Aspira Women’s Health, Inc. (Nasdaq: AWH) will report its third-quarter financial results for the period ending September 30, 2021, on November 10, 2021, before the market opens. Following the release, an investor conference call and webcast will be held at 8:30 a.m. ET. The company focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its products include OVA1® and OVERA® for ovarian malignancy detection, with ongoing research into new testing solutions like OVANEX™ and EndoCheck™.

Aspira Women’s Health Inc. (Nasdaq: AWH) has partnered with Genoox to enhance women's health through improved testing for complex diseases. This collaboration aims to integrate their genomic data platforms, streamlining access to critical genetic information. It intends to leverage advanced data analytics to accelerate the development of diagnostic solutions, particularly for conditions like ovarian cancer. Both companies foresee expanding their product offerings and enhancing risk assessment tools through this innovative partnership.

Aspira Women’s Health Inc (AWH) and the Black Women’s Health Imperative held a briefing on September 27, 2021, addressing ovarian cancer diagnostics and treatment gaps. Key discussions included the need for education, research funding, improved detection methods, and insurance coverage, especially for underserved populations. Aspira promoted its OVA1plus risk assessment tool, emphasizing its effectiveness among Black women. Ovarian cancer has a mortality rate exceeding 50%, with 60 new cases daily in the U.S. The briefing attracted over 350 attendees, including prominent Congress members, highlighting the urgency to tackle health disparities.

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced partnerships with two leading U.S. women’s health networks and two independent laboratories to enhance access to its OVA1plus™ testing. The agreements, made post the launch of Aspira Synergy, which exceeded commercial milestones, will allow in-house genetic testing for over 950,000 patients annually.

This decentralized platform enables healthcare providers to conduct genetic and ovarian cancer risk assessments directly, leveraging AI technology for improved diagnostics and early detection.

Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021, at 4:40 PM ET. The event will include virtual 1x1 meetings with management, and interested parties can request meetings via email. Aspira focuses on innovative testing options for women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. The company is developing next-generation products such as OVAWatch and EndoCheck. For more details, visit www.aspirawh.com.

Aspira Women’s Health (Nasdaq: AWH) is marking Ovarian Cancer Awareness Month by ringing the closing bell at NASDAQ on September 9, 2021, to promote awareness and access to risk assessment for ovarian cancer. Despite being a leading cause of cancer deaths in women, awareness remains low. Aspira aims to enhance knowledge on ovarian cancer through participation in various events, including keynote speeches and congressional briefings. The company is focused on developing innovative testing solutions to improve women’s healthcare and reduce disparities in risk assessment.

Aspira Women’s Health reported a strong second quarter for 2021, with total revenue increasing by 141% to $1.8 million compared to $743,000 in Q2 2020. The volume of OVA1 tests grew by 85% to 4,553 accessions. A recent publication supports OVA1's superiority over standard care for early-stage ovarian cancer detection. However, expenses surged, with research and development costs rising 287% and sales and marketing up by 132%. The company ended the quarter with $53 million in cash but reported a $6.5 million operational cash burn.